SIC 2835 – In Vitro and In Vivo Diagnostic Substances
Valuation | |
---|---|
Market Cap ($M) | 429.66 |
Enterprise Value ($M) | 436.90 |
Book Value ($M) | 87.27 |
Book Value / Share | 1.64 |
Price / Book | 4.92 |
NCAV ($M) | 9.10 |
NCAV / Share | 0.17 |
Price / NCAV | 47.22 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.27 |
Return on Assets (ROA) | -0.25 |
Return on Equity (ROE) | -0.35 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 3.94 |
Current Ratio | 4.73 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 45.93 |
Assets | 124.10 |
Liabilities | 36.83 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D | Telegraph Hill Partners IV, L.P. | 70.80 | 47.21 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
37,058 | 148,728 | 24.92 | |
28,829 | 231,961 | 12.43 | |
53,588 | 267,535 | 20.03 | |
(click for more detail) |
Similar Companies | |
---|---|
TARA – Protara Therapeutics, Inc. | TBPH – Theravance Biopharma, Inc. |
TCRX – TScan Therapeutics, Inc. | TLPH – Talphera, Inc. |
TNGX – Tango Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io